VIMTA LABS
|
|
| BOM : 524394     NSE : VIMTALABS     | |
| LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 03,2026 |
|
Price(EOD): ₹ 514.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Business Support |
| MCap: ₹ 2,299.14 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| VIMTA LABS | 12.6% | 7.9% | -3.9% |
| SAGILITY | -2.8% | -3.3% | 4.3% |
| SYNGENE INTERNATIONAL | -4.7% | -8.2% | -32.2% |
| PRIME FOCUS | -7.1% | -26.3% | 116.7% |
| INTERNATIONAL GEMOLOGICAL INSTITUTE | -2.6% | 3.4% | -1.1% |
| INDEGENE | -0.1% | -2.8% | -11.7% |
| NESCO | -5.4% | -9.9% | 25.7% |
| LATENT VIEW ANALYTICS | -0.9% | 7.5% | -22.7% |
| SUN PHARMA ADVANCED RESEARCH COMPANY | -6.1% | 48.9% | 20.1% |
FUNDAMENTAL ANALYSIS OF VIMTA LABS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF VIMTA LABS
 | Ratio | Standalone | |
|---|---|---|
|
P/E P/B P/S |
29.64
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 77.51 Cr
[Latest Qtr - Mar2026 - Standalone Results ] 5.11
P/B Calculated based on Book Value of Rs 449.51 Cr
[Latest Year - Mar2026 - Standalone Results ] 5.64
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Mar2026 - Standalone Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
73% 118% 129% |
SHARE PRICE MOMENTUM OF VIMTA LABS
VIMTA LABS vs SENSEX
DEBT OF VIMTA LABS
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2026 2025 2024 Avg_3yrs |
0.01 0.02 0.06 0.03 |
- - 0.06 0.02 |
|
[Last Annual Data : Mar2026]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF VIMTA LABS
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF VIMTA LABS
| Standalone | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
10.76% 15% 24.29% 20.06% |
15.68% 19.16% 16.06% 15.25% |
| QtrlyTrend |
8 | |
| Latest Qtr: Mar2026 | ||
| Quarterly Result Analysis → | ||
VIMTA LABS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | -2% | 4.3% | 9% |
You may also like the below Video Courses
FAQ about VIMTA LABS
Is VIMTA LABS good for long term investment?
As on Jun 03,2026, the Fundamentals of VIMTA LABS look Strong and hence it may be good for long term investment! See Financial Performance of VIMTA LABS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is VIMTA LABS UnderValued or OverValued?
As on Jun 03,2026, VIMTA LABS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of VIMTA LABS ?
As on Jun 03,2026, the Intrinsic Value of VIMTA LABS is Rs. 236.27 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 296.86
Fair Value [Median EV / Sales Model] : Rs. 236.27
Fair Value [Median Price / Sales Model] : Rs. 224.40
Estimated Median Fair Value of VIMTA LABS : Rs. 236.27
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is VIMTA LABS trading at a Premium or Discount?
As on Jun 03,2026, VIMTA LABS is trading at a Premium of 118% based on the estimates of Median Intrinsic Value!SAGILITY LTD vs SYNGENE INTERNATIONAL LTD vs PRIME FOCUS LTD
INTERNATIONAL GEMOLOGICAL INSTITUTE LTD vs INDEGENE LTD vs NESCO LTD